Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Zhijian Xiao, Liang Liu, Zefeng Xu, Tiejun Qin, Yue Zhang & Tianjiao Zhang. (2010) Low-dose melphalan in myelodysplastic syndromes: an effective treatment for elderly RAEB-I or II patients?. Leukemia & Lymphoma 51:3, pages 549-551.
Read now
Read now
Articles from other publishers (15)
Giuseppe Visani, Felicetto Ferrara, Francesco Di Raimondo, Federica Loscocco, Fabio Fuligni, Stefania Paolini, Valentina Zammit, Eleonora Spina, Marco Rocchi, Axel Visani, Pier Paolo Piccaluga & Alessandro Isidori. (2017) Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. Leukemia Research 62, pages 77-83.
Crossref
Crossref
Kathrin Bauer, Franz Hutzschenreuter, Nicole Skoetz, Ina Monsef, Karl-Anton Kreuzer & Andreas Engert. (2016) Low dose cytarabine monotherapy for myelodysplastic syndromes. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Z. Cai, X. Zhang, D.F. Lu & J.N. Gan. (2012) A New Chemiluminescence Method for Determination of Cytosine Arabinoside in Pharmaceutical Preparations. Bulletin of the Korean Chemical Society 33:1, pages 171-176.
Crossref
Crossref
Kathrin Bauer, Franz Hutzschenreuter, Nicole Skoetz, Ina Monsef, Karl-Anton Kreuzer & Andreas Engert. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Gail J. Roboz, Ellen K. Ritchie, Tania Curcio, Michael Samuel, Juliette Provenzano, Javier Segovia, Paul J. Christos, Susan Mathew, Sandra Allen-Bard & Eric J. Feldman. (2011) Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leukemia Research 35:4, pages 522-525.
Crossref
Crossref
Guillermo Garcia-ManeroPierre Fenaux. (2011) Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes. Journal of Clinical Oncology 29:5, pages 516-523.
Crossref
Crossref
John F. Seymour, Pierre Fenaux, Lewis R. Silverman, Ghulam J. Mufti, Eva Hellström-Lindberg, Valeria Santini, Alan F. List, Steven D. Gore, Jay Backstrom, David McKenzie & C.L. Beach. (2010) Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology 76:3, pages 218-227.
Crossref
Crossref
Pierre Fenaux, Norbert Gattermann, John F. Seymour, Eva Hellström-Lindberg, Ghulam J. Mufti, Ulrich Duehrsen, Steven D. Gore, Fernando Ramos, Odile Beyne-Rauzy, Alan List, David McKenzie, Jay Backstrom & Charles L. Beach. (2010) Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. British Journal of Haematology 149:2, pages 244-249.
Crossref
Crossref
Junichi Kitagawa, Takeshi Hara, Hisashi Tsurumi, Nobuhiro Kanemura, Senji Kasahara, Masahito Shimizu & Hisataka Moriwaki. (2010) Cell Cycle-Dependent Priming Action of Granulocyte Colony-Stimulating Factor (G-CSF) Enhances in vitro Apoptosis Induction by Cytarabine and Etoposide in Leukemia Cell Lines. Journal of Clinical and Experimental Hematopathology 50:2, pages 99-105.
Crossref
Crossref
Anita Ryningen, Camilla Stapnes, Philippe Lassalle, Matthias Corbascio, Bjørn-Tore Gjertsen & Øystein Bruserud. (2009) A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia Research 33:6, pages 779-787.
Crossref
Crossref
Richard M. Stone. (2008) Are new agents really making a difference in MDS?. Best Practice & Research Clinical Haematology 21:4, pages 639-646.
Crossref
Crossref
Nobuhiro Kanemura, Hisashi Tsurumi, Senji Kasahara, Takeshi Hara, Toshiki Yamada, Michio Sawada, Naoe Goto, Jun‐ichi Kitagawa, Masahito Shimizu, Masami Oyama & Hisataka Moriwaki. (2007) Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony‐stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematological Oncology 26:1, pages 33-38.
Crossref
Crossref
Hisashi Tsurumi, Nobuhiro Kanemura, Takeshi Hara, Senji Kasahara, Toshiki Yamada, Michio Sawada, Masami Oyama & Hisataka Moriwaki. (2007) Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide. Journal of Cancer Research and Clinical Oncology 133:8, pages 547-553.
Crossref
Crossref
H Zwierzina, S Suciu, J Loeffler-Ragg, R Neuwirtova, P Fenaux, M Beksac, J Harousseau, V Nuessler, J Cermak, G Solbu, R Willemze, T de Witte & S Amadori. (2005) Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 19:11, pages 1929-1933.
Crossref
Crossref
. (2005) Current Awareness in Hematological Oncology. Hematological Oncology 22:3, pages 135-142.
Crossref
Crossref